Post Cycle Therapy (PCT) restores your natural testosterone after a cycle of SARMs, steroids, or peptides. In 2025, Clomid, Nolvadex, Toremifene, Raloxifene, and Enclomiphene remain the best SERMs for recovery.
This guide covers dosage protocols, stacking strategies, and the latest clinical and community-backed practices shaping PCT this year.
🧪 Top 5 SERMs for PCT in 2025
| SERM | Pros | Cons | Best Use Case |
|---|---|---|---|
| Clomid (Clomiphene) | Strong LH/FSH stimulation, proven results | Mood swings, visual disturbances | Heavy suppression or steroid cycles |
| Nolvadex (Tamoxifen) | Excellent estrogen control, fewer mood effects | Slower LH response | Milder cycles or stacked with Clomid |
| Toremifene | Better lipid profile, reduced clotting risk | Limited research availability | Users concerned with cholesterol |
| Raloxifene | Strong anti-estrogen for gyno prevention | Weak LH stimulation | Treating or preventing gynecomastia |
| Enclomiphene | Fewer side effects, cleaner hormonal profile | Costly, less available | Natural recovery or TRT bridge |
These SERMs form the foundation of modern PCT, with recovery tailored by cycle intensity, biomarker tracking, and side effect tolerance.
💊 Best Dosage Protocols by Cycle Type
1. Clomid (Clomiphene)
- Dosage: 50 mg/day for 2 weeks, then 25 mg/day for 2 weeks
- Best For: Heavy suppression (RAD-140, YK-11, or steroids)
- Pro Tip: Stack with Nolvadex to prevent estrogen rebound
2. Nolvadex (Tamoxifen)
- Dosage: 20–40 mg/day for 4 weeks
- Best For: Mild to moderate suppression
- Pro Tip: Works best for mood stability and estrogen management
3. Enclomiphene
- Dosage: 12.5–25 mg/day for 3–4 weeks
- Best For: Natural testosterone recovery or bridging off TRT
- Pro Tip: Maintains LH/FSH with fewer side effects than Clomid
4. Toremifene
- Dosage: 60 mg/day for 2 weeks, then 30 mg/day for 2 weeks
- Best For: Users managing cholesterol or cardiovascular risk
- Pro Tip: A safer long-term option compared to Nolvadex
✅ Best Practices for PCT in 2025
- Start 1–3 days after SARMs or 2 weeks post long esters
- Combine Clomid + Nolvadex for highly suppressive cycles
- Use blood tests (LH, FSH, total/free testosterone) to track recovery
- Include support supplements like NAC, DIM, or ashwagandha
- Adjust protocol length between 4–6 weeks based on suppression level
⚠️ Common PCT Mistakes
- Skipping PCT after SARMs: Even mild SARMs suppress natural testosterone.
- Relying on OTC “PCT” supplements: These cannot replace real SERMs.
- Mistiming PCT: Starting too early or too late delays recovery.
- Confusing Enclomiphene with Clomid: Their actions and dosing differ.
🔬 Latest PCT Trends (2025)
- Microdosed SERM protocols for smoother recovery
- Enclomiphene explored as a potential standalone TRT replacement
- Toremifene re-evaluated for heart and lipid safety
- Hybrid PCT stacks mixing SERMs, adaptogens, and mild aromatase inhibitors
- Blood marker–based cycles becoming the new standard
❓ Frequently Asked Questions
1. Which SERM is best for PCT in 2025?
Clomid and Nolvadex together remain the strongest option for deep suppression. Enclomiphene provides cleaner recovery with fewer side effects.
2. When should I start PCT after SARMs or steroids?
Start 1–3 days after SARMs or 2 weeks post long esters for best results.
3. Is Enclomiphene better than Clomid?
Yes. It offers fewer mood swings and side effects, but Clomid may be stronger after heavy anabolic cycles.
4. Can Nolvadex work alone?
Yes, for mild suppression. Stacking with Clomid accelerates recovery.
5. How do I know if my PCT worked?
Run bloodwork 4–6 weeks after finishing PCT. Normalized LH, FSH, and testosterone indicate recovery.
6. Can supplements replace SERMs?
No. Supplements can support health but cannot restart hormone production like SERMs.
📌 Key Takeaways
- Select your SERM and dosage based on cycle type and suppression level
- Clomid + Nolvadex is still the gold standard protocol
- Enclomiphene and Toremifene provide cleaner, modern options
- Always confirm hormonal recovery through bloodwork before starting another cycle
Related Articles:
